New Interventional Guidewires Unveiled at TCT 2010
Lake Region Medical Releases Next Generation Guidewires for Cardiovascular
and Peripheral Interventions; OEM Well Positioned with Medical Device Companies
as New Tax Burden Falls on Industry
Lake Region Medical is extending its global leadership in
interventional guidewires and remains well positioned to provide essential R&D partnership opportunities
with major Medical Device companies with the release of new guidewires for cardiovascular and
Lake Region Medical's expanded product portfolio will be introduced at the 22nd annual Transcatheter
Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research
Foundation, September 21-25, 2010, in Washington, D.C., at a time when the Medical Device (MD)
industry is entering a period during which it must bear a significant tax load under the new U.S.
Healthcare bill. The impacts will continue to be newsworthy.
Under provisions of the Patient Protection And Affordable Care Act (PPACA), beginning in 2013,
manufacturers, producers and importers of medical devices will pay a 2.3 percent excise tax on
all sales, which according to one estimate will amount to some $4 billion annually while having "a
significant dampening affect on funding available for future research and development," according
to the Advanced Medical Technology Association.
Jim Mellor, vice president of sales and marketing at Lake Region Medical notes, "Leading MD marketers
are increasingly focused on core technologies and will rely on vendor partnering relationships to
deliver R&D and manufacturing of critical, but non-core devices, such as guidewires and other
interventional accessories. For Lake Region Medical, the pressure on major MD companies
presents a growing opportunity to further serve the industry." The 64-year-old privately held
company based in Minneapolis is the established global leader in guidewires for diagnostic and
interventional applications. And it will unveil new guidewire products at TCT designed specifically for
interventional applications. The new interventional guidewires are designed around a platform of
proprietary technologies. (See Backgrounder).
New products include:
FLAGSHIP™ Frontline Guidewires – Employ TWISTER™ and MICRORIDGE™ Core Wire
Technologies to deliver industry leading frontline performance.
TRAILRUNNER™ Coronary Guidewires – Bi-metal core design enhances frontline performance in
procedures requiring a highly excellent deliverability, torque control retention and enough support to
deliver most interventional devices.
HYDRATE™ Coronary Guidewires – Provide smooth tracking and excellent steering control for
enhanced access in complex anatomy during frontline PTCA.
FLAGSHIP™ HS Crossing Guidewires – Deliver superior crossing performance during difficult lesion
cases through a combination of performance enhancing technologies including TWISTER™,
MICRORIDGE™ and WEDGE™.
RAILRUNNER™ Coronary Crossing Guidewires – Tapered and non-tapered
distal tip designs, excellent torque control and dual tip coatings ensure effective access to highly
stenosed lesions during PTCA procedures.
FLAGSHIP™ SB Side-Branch Access Guidewires – Unique J-tip design reduces guidewire
prolapse in the main vessel and transmits force in the direction of the target side-branch vessel during
EXCURSION™ Transradial Coronary Guidewires – For transradial approach to frontline PTCA.
Low-profile design and excellent torque control facilitate guidewire and device delivery in small,
tortuous vessel anatomy.
RAPIDWIRE™ and RAPIDWIRE PLUS™ Peripheral Interventional Guidewires – Provides excellent
torque control and distal vessel access within smaller, complex, peripheral vasculature and
TAXI® Endoscopic Guidewires – Features dual-colored spiral pattern for enhanced visualization,
nitinol core for greater kink resistance, radiopaque distal tip for easy positioning and device
exchange, and highly lubricious coating of both tip and wire for enhanced performance in endoscopic